Companion Medical receives FDA clearance

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) announced today that
Companion Medical,Inc receives 510(k) clearance from the FDA for the InPen®
system, an intelligent insulin administration system and smartphone application.
Diamyd Medical owns 8.5% of Companion Medical and holds the distribution rights
for future products in the Nordic countries.
Companion Medical’s InPen® is cleared in the US for use with Ely Lilly’s
Humalog® or Novo Nordisk’s Novolog® rapid acting insulin. The InPen® application
is cleared for Apple iOS and an Android version is planned for later in 2016.
Companion Medical has also applied for a CE Mark for market approval in Europe.

Diamyd Medical owns 8.5% of Companion Medical and holds the distribution rights
to Companion Medical’s future products in the Nordic countries.

For additional details regarding the FDA clearance see Companion Medical’s press
release, www.companion-medical.com.

About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through
pharmaceutical development and investments in stem cell and medical technology.

Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy
(ABT) based on the exclusively licensed GAD-molecule. The Company’s licensed
technologies for GABA and Gliadin have also potential to become key pieces of
the puzzle of a future solution to prevent, treat or cure autoimmune diabetes,
and also certain inflammatory diseases. At this time six clinical studies are
ongoing with Diamyd®. Diamyd Medical is one of the major shareholders in the
stem cell company Cellaviva AB. Stem cells can be expected to be used in
Personalized Regenerative Medicine (PRM), for example for restoration of beta
cell mass in diabetes patients where the autoimmune component of the disease has
been arrested. Diamyd Medical also has holdings in the medtech company Companion
Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc.,
Pittsburgh, USA.

Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the
ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41. E-mail: ulf.hannelius@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8
661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.